← All trials
NCT03846362
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 1, 2019
- Primary completion
- Jan 31, 2024
- Completion date
- Jan 31, 2025
- First posted
- —
- Last posted
- —
- Enrollment
- 100
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Federal Research Institute of Pediatric Hematology, Oncology and ImmunologyLead sponsor
- Physicians, Innovations, Science for Children FundCollaborator
- Government of RussiaStudy chair
- Government of RussiaStudy director
- Government of RussiaOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.